Table 1.

Demographic and clinical variables for treated active surveillance patients

Demographic and clinical variables	Patients treated for preference (n=12)	Patients treated for clinical progression (n=17)	Combined (n=29)	p for preference vs. progression
Age (mean ± SD)	62.6±9.3 years	68.2±8.3 years	65.9±9.0 years	0.10
Sex (% male)	8 (66.7%)	14 (82.4%)	22 (75.9%)	0.40
Initial tumor presentation size (mean ± SD)	2.38±0.68 cm	2.58±0.59 cm	2.50±0.63 cm	0.41
Biopsy histology	7 clear-cell RCC (58.3%) 1 clear-cell papillary RCC (8.3%) 1 papillary type 1 (8.3%) 2 papillary type 2 (16.7%) 1 papillary NOS (8.3%)	14 clear-cell RCC (82.4%) 1 papillary type 1 (5.9%) 1 papillary type 2 (5.9%) 1 mixed (papillary type 1, clear cell RCC; 5.9%)	21 clear-cell RCC (72.4%) 1 clear-cell papillary RCC (3.5%) 2 papillary type 1 (6.9%) 3 papillary type 2 (10.3%) 1 mixed (papillary type 1, clear-cell RCC; 3.5%) 1 papillary NOS (3.5%)	0.41
Maximum biopsy grade	4 grade 1 (50.0%) 3 grade 2 (37.5%) 1 grade 3 (12.5%) 4 missing	8 grade 1 (50.0%) 8 grade 2 (50.0%) 1 missing	12 grade 1 (50.0%) 11 grade 2 (45.8%) 1 grade 3 (4.2%) 5 missing	0.46
Reasons for clinical progression	N/A	12 growth >0.5 cm/year for 2 years (70.6%) 13 absolute size >4 cm (76.5%) 8 volume doubling <1 year (47.1%)*	N/A	N/A

^*Totals exceed 100% as patients may meet more than one criterion.

NOS: not otherwise specified; RCC: renal cell carcinoma; SD: standard deviation.